Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gianpaolo di Santo

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
PET Clinics|March 29, 2023
Imaging FibrosisAnna Sviridenko, Gianpaolo di Santo, Irene Virgolini
Seminars in Nuclear Medicine|March 15, 2024
Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and AlternativesGiulia Santo, Gianpaolo Di Santo, Irene Virgolini
European Journal of Nuclear Medicine and Molecular Imaging|February 14, 2026
Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directionsIrene J Virgolini, Gianpaolo Di Santo, Giulia Santo
Theranostics|January 22, 2024
Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023Gianpaolo di Santo, Giulia Santo, Anna Sviridenko, et al.
Journal of Neuroendocrinology|March 10, 2025
Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumorsGiulia Santo, Gianpaolo di Santo, Francesco Cicone, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 21, 2025
Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [<sup>18</sup>F]FDG-positive metastatic neuroendocrine tumorsGianpaolo di Santo, Giulia Santo, Lukas Wirth, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 8, 2004
Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancerGiuseppe De Vincentis, Silvia Remediani, Alexandra D Varvarigou, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2023
Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the <sup>68</sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid CancerElisabeth von Guggenberg, Christian Uprimny, Maximilian Klinger, et al.
Frontiers in Oncology|September 17, 2025
Are brain metastases a special issue in POLE-mutated endometrial cancer? a case report seriesChristoph Ebner, Kristina Lindemann, Gunnar Kristensen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 6, 2026
Real-world outcomes of [<sup>177</sup>Lu]Lu-PSMA-I&T in [<sup>18</sup>F]FDG-positive metastatic castration-resistant prostate cancer: factors related to response and survivalGiulia Santo, Gianpaolo di Santo, Ariane Kronthaler, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
PET Clinics|March 29, 2023
Imaging FibrosisAnna Sviridenko, Gianpaolo di Santo, Irene Virgolini
Seminars in Nuclear Medicine|March 15, 2024
Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and AlternativesGiulia Santo, Gianpaolo Di Santo, Irene Virgolini
European Journal of Nuclear Medicine and Molecular Imaging|February 14, 2026
Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directionsIrene J Virgolini, Gianpaolo Di Santo, Giulia Santo
Theranostics|January 22, 2024
Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023Gianpaolo di Santo, Giulia Santo, Anna Sviridenko, et al.
Journal of Neuroendocrinology|March 10, 2025
Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumorsGiulia Santo, Gianpaolo di Santo, Francesco Cicone, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 21, 2025
Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [<sup>18</sup>F]FDG-positive metastatic neuroendocrine tumorsGianpaolo di Santo, Giulia Santo, Lukas Wirth, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 8, 2004
Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancerGiuseppe De Vincentis, Silvia Remediani, Alexandra D Varvarigou, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2023
Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the <sup>68</sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid CancerElisabeth von Guggenberg, Christian Uprimny, Maximilian Klinger, et al.
Frontiers in Oncology|September 17, 2025
Are brain metastases a special issue in POLE-mutated endometrial cancer? a case report seriesChristoph Ebner, Kristina Lindemann, Gunnar Kristensen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 6, 2026
Real-world outcomes of [<sup>177</sup>Lu]Lu-PSMA-I&T in [<sup>18</sup>F]FDG-positive metastatic castration-resistant prostate cancer: factors related to response and survivalGiulia Santo, Gianpaolo di Santo, Ariane Kronthaler, et al.
Pageof 3